Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 29, 2020 - Issue 2: NASH and NAFLD: Emerging drugs, therapeutic targets and translational and clinical challenges
Submit an article Journal homepage
6,293
Views
13
CrossRef citations to date
0
Altmetric
Review

Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)

Daren R. UreHepion Pharmaceuticals Inc, Edmonton, AB, CanadaCorrespondence[email protected]
View further author information
,
Daniel J. TrepanierHepion Pharmaceuticals Inc, Edmonton, AB, CanadaView further author information
,
Patrick R. MayoHepion Pharmaceuticals Inc, Edmonton, AB, CanadaView further author information
&
Robert T. FosterHepion Pharmaceuticals Inc, Edmonton, AB, CanadaView further author information
Pages 163-178 | Received 07 Nov 2019, Accepted 08 Dec 2019, Published online: 23 Dec 2019

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Deepak M W Balak, Stefano Piaserico & Ismail Kasujee. (2021) Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. Psoriasis: Targets and Therapy 11, pages 151-168.
Read now
Mervat Naguib, Mahmoud Abou Elfotouh & Mohamed-Naguib Wifi. (2021) Elevated Serum Cyclophilin D Level is Associated with Nonalcoholic Fatty Liver Disease and Higher Fibrosis Scores in Patients with Diabetes Mellitus. International Journal of General Medicine 14, pages 4665-4675.
Read now

Articles from other publishers (11)

Inês Domingues, Isabelle A. Leclercq & Ana Beloqui. (2023) Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery. Journal of Controlled Release 363, pages 415-434.
Crossref
Kelly Torosian, Esha Lal, Arthur Kavanaugh, Rohit Loomba, Veeral Ajmera & Monica Guma. (2023) Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Seminars in Arthritis and Rheumatism 59, pages 152165.
Crossref
Huihui Yang, Weiwei Yao & Jinfei Yang. (2023) Overview of the development of HBV small molecule inhibitors. European Journal of Medicinal Chemistry 249, pages 115128.
Crossref
Stephen A. Harrison, Patrick R. Mayo, Todd M. Hobbs, Carlos Canizares, Erin P. Foster, Caroline Zhao, Daren R. Ure, Daniel J. Trepanier, Jill A. Greytok & Robert T. Foster. (2022) Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH. Hepatology Communications 6:12, pages 3379-3392.
Crossref
Ellen Remenchik, Patrick R. Mayo, Todd M. Hobbs, Jill A. Greytok, Erin P. Foster, Caroline Zhao, Daren Ure, Daniel J. Trepanier & Robert T. Foster. (2022) Effect of a High‐Fat Meal on Single‐Dose Rencofilstat (CRV431) Oral Bioavailability in Healthy Human Subjects. Clinical Pharmacology in Drug Development.
Crossref
Nicholas W. S. Chew, Cheng Han Ng, Emily Truong, Mazen Noureddin & Kris V. Kowdley. (2022) Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Seminars in Liver Disease 42:03, pages 379-400.
Crossref
Sukhpal Singh, Upasana Ganguly, Soumya Pal, Gourav Chandan, Rahul Thakur, Reena V. Saini, Sankha Shubhra Chakrabarti, Bimal K. Agrawal & Sasanka Chakrabarti. (2022) Protective effects of cyclosporine A on neurodegeneration and motor impairment in rotenone-induced experimental models of Parkinson's disease. European Journal of Pharmacology 929, pages 175129.
Crossref
Annamaria Haleckova, Ondrej Benek, Lucie Zemanová, Rafael Dolezal & Kamil Musilek. (2022) Small‐molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria‐related diseases. Medicinal Research Reviews.
Crossref
Man Zhao, Huazhong Xie, Hao Shan, Zhihua Zheng, Guofeng Li, Min Li & Liang Hong. (2022) Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 23:3, pages 1102.
Crossref
Feng-Xia Li, Qing-Zhou Zhang, Shi-Jun Li, Guang Lin, Xiang-Yu Huo, Yu Lan & Zhen Yang. (2021) Semisynthesis of CRV431. Organic Letters 23:9, pages 3421-3425.
Crossref
Nalini Sodum, Gautam Kumar, Sree Lalitha Bojja, Nitesh Kumar & C. Mallikarjuna Rao. (2021) Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacological Research 167, pages 105484.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.